Answers are grounded in this paper and cite their sources.
Observational analysis compares diagnostic accuracy of VISITECT® CD4 and Partec® CyFlow for advanced HIV disease, suggesting improved outcomes in resource-limited settings.
Abstract We evaluated the diagnostic performance and practicability of the VISITECT® CD4 Lateral Flow Assay for identifying advanced HIV disease (AHD) across 334 facilities in Nigeria. In two phases, 468 participants were tested with VISITECT® CD4 and Partec® CyFlow. VISITECT® CD4 achieved a sensitivity of 100.0% and specificity of 89.8% for detecting CD4 ≤ 200 cells/mm³. The positive predictive value (PPV) was 91.3% (95% CI: 87.4–94.1), and the negative predictive value (NPV) was 100% (95% Cl: 98.1–100.0). Overall diagnostic accuracy was 95.1% (95% CI: 92.8–96.8). We recommend its use to enhance timely AHD detection and improve linkage to prophylactic interventions in resource-limited settings.
No takes yet. Share an insight, caveat, or question.
Nwofe et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: